TLR-4 can significantly reduce the efficacy of 5-FU by promoting the activation of the NLRP3 inflammasome in myeloid-derived suppressor cells (MDSCs) and macrophages within the tumor microenvironment (TME), triggering an inflammatory cascade reaction. Here, TLR4 is linked to neoplasm.